May 19, 2020
Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix
May 19, 2020
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
Jan 08, 2020
U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of MYCAMINE® (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age
Jan 08, 2020
SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Nov 12, 2019
SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update
Oct 24, 2019
SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date
Oct 02, 2019
SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
Sep 24, 2019
Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
Sep 16, 2019
Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
Sep 09, 2019
FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications
Apr 30, 2019
Caspofungin Market to Touch US$ 496.20 Million by 2027, Says TMR
Feb 28, 2019
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
Feb 19, 2019
Antifungal Drugs Market Worth $17.72 Billion by 2023 at 3.7% CAGR, Says AMR
Jan 30, 2019
SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies
Nov 13, 2018
Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
Aug 09, 2018
SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update
Jul 18, 2018
The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078
Jun 11, 2018
SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018
May 24, 2018
SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018
Apr 30, 2018
Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species